712 related articles for article (PubMed ID: 28435985)
1. Elucidating the Aβ42 Anti-Aggregation Mechanism of Action of Tramiprosate in Alzheimer's Disease: Integrating Molecular Analytical Methods, Pharmacokinetic and Clinical Data.
Kocis P; Tolar M; Yu J; Sinko W; Ray S; Blennow K; Fillit H; Hey JA
CNS Drugs; 2017 Jun; 31(6):495-509. PubMed ID: 28435985
[TBL] [Abstract][Full Text] [Related]
2. Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain.
Hey JA; Kocis P; Hort J; Abushakra S; Power A; Vyhnálek M; Yu JY; Tolar M
CNS Drugs; 2018 Sep; 32(9):849-861. PubMed ID: 30076539
[TBL] [Abstract][Full Text] [Related]
3. Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer's Disease.
Hey JA; Yu JY; Versavel M; Abushakra S; Kocis P; Power A; Kaplan PL; Amedio J; Tolar M
Clin Pharmacokinet; 2018 Mar; 57(3):315-333. PubMed ID: 29063518
[TBL] [Abstract][Full Text] [Related]
4. Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer's Disease Suggest Disease Modification Potential.
Abushakra S; Porsteinsson A; Scheltens P; Sadowsky C; Vellas B; Cummings J; Gauthier S; Hey JA; Power A; Wang P; Shen L; Tolar M
J Prev Alzheimers Dis; 2017; 4(3):149-156. PubMed ID: 29182706
[TBL] [Abstract][Full Text] [Related]
5. Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval.
Tolar M; Abushakra S; Hey JA; Porsteinsson A; Sabbagh M
Alzheimers Res Ther; 2020 Aug; 12(1):95. PubMed ID: 32787971
[TBL] [Abstract][Full Text] [Related]
6. Clinical Benefits of Tramiprosate in Alzheimer's Disease Are Associated with Higher Number of APOE4 Alleles: The "APOE4 Gene-Dose Effect".
Abushakra S; Porsteinsson A; Vellas B; Cummings J; Gauthier S; Hey JA; Power A; Hendrix S; Wang P; Shen L; Sampalis J; Tolar M
J Prev Alzheimers Dis; 2016; 3(4):219-228. PubMed ID: 29199323
[TBL] [Abstract][Full Text] [Related]
7. Tramiprosate.
Wright TM
Drugs Today (Barc); 2006 May; 42(5):291-8. PubMed ID: 16801992
[TBL] [Abstract][Full Text] [Related]
8. Domino-like effect of C112R mutation on ApoE4 aggregation and its reduction by Alzheimer's Disease drug candidate.
Nemergut M; Marques SM; Uhrik L; Vanova T; Nezvedova M; Gadara DC; Jha D; Tulis J; Novakova V; Planas-Iglesias J; Kunka A; Legrand A; Hribkova H; Pospisilova V; Sedmik J; Raska J; Prokop Z; Damborsky J; Bohaciakova D; Spacil Z; Hernychova L; Bednar D; Marek M
Mol Neurodegener; 2023 Jun; 18(1):38. PubMed ID: 37280636
[TBL] [Abstract][Full Text] [Related]
9. Scrutiny of the mechanism of small molecule inhibitor preventing conformational transition of amyloid-β
Shuaib S; Goyal B
J Biomol Struct Dyn; 2018 Feb; 36(3):663-678. PubMed ID: 28162045
[TBL] [Abstract][Full Text] [Related]
10. Inhibiting and Remodeling Toxic Amyloid-Beta Oligomer Formation Using a Computationally Designed Drug Molecule That Targets Alzheimer's Disease.
Downey MA; Giammona MJ; Lang CA; Buratto SK; Singh A; Bowers MT
J Am Soc Mass Spectrom; 2019 Jan; 30(1):85-93. PubMed ID: 29713966
[TBL] [Abstract][Full Text] [Related]
11. An α-helix mimetic oligopyridylamide, ADH-31, modulates Aβ
Kaur A; Goyal D; Goyal B
Phys Chem Chem Phys; 2020 Dec; 22(48):28055-28073. PubMed ID: 33289734
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of C-Terminal Fragments of Amyloid β-Protein as Aβ Inhibitors: Do C-Terminal Interactions Play a Key Role in Their Inhibitory Activity?
Zheng X; Wu C; Liu D; Li H; Bitan G; Shea JE; Bowers MT
J Phys Chem B; 2016 Mar; 120(8):1615-23. PubMed ID: 26439281
[TBL] [Abstract][Full Text] [Related]
13. Insights into the inhibitory mechanism of a resveratrol and clioquinol hybrid against Aβ
Saini RK; Shuaib S; Goyal D; Goyal B
J Biomol Struct Dyn; 2019 Aug; 37(12):3183-3197. PubMed ID: 30582723
[TBL] [Abstract][Full Text] [Related]
14. The ongoing search for small molecules to study metal-associated amyloid-β species in Alzheimer's disease.
Savelieff MG; DeToma AS; Derrick JS; Lim MH
Acc Chem Res; 2014 Aug; 47(8):2475-82. PubMed ID: 25080056
[TBL] [Abstract][Full Text] [Related]
15. Review of valiltramiprosate (ALZ-801) for the treatment of Alzheimer's disease: a novel small molecule with disease modifying potential.
Lee D; Antonsdottir IM; Clark ED; Porsteinsson AP
Expert Opin Pharmacother; 2024 May; ():1-9. PubMed ID: 38814590
[TBL] [Abstract][Full Text] [Related]
16. Effect of tramiprosate in patients with mild-to-moderate Alzheimer's disease: exploratory analyses of the MRI sub-group of the Alphase study.
Gauthier S; Aisen PS; Ferris SH; Saumier D; Duong A; Haine D; Garceau D; Suhy J; Oh J; Lau W; Sampalis J
J Nutr Health Aging; 2009 Jun; 13(6):550-7. PubMed ID: 19536424
[TBL] [Abstract][Full Text] [Related]
17. Impact of amyloid-beta changes on cognitive outcomes in Alzheimer's disease: analysis of clinical trials using a quantitative systems pharmacology model.
Geerts H; Spiros A; Roberts P
Alzheimers Res Ther; 2018 Feb; 10(1):14. PubMed ID: 29394903
[TBL] [Abstract][Full Text] [Related]
18. Amyloid-peptide β 42 Enhances the Oligomerization and Neurotoxicity of apoE4: The C-terminal Residues Leu279, Lys282 and Gln284 Modulate the Structural and Functional Properties of apoE4.
Dafnis I; Argyri L; Chroni A
Neuroscience; 2018 Dec; 394():144-155. PubMed ID: 30367942
[TBL] [Abstract][Full Text] [Related]
19. Aβ42 oligomer-specific antibody ALZ-201 reduces the neurotoxicity of Alzheimer's disease brain extracts.
Sandberg A; Berenjeno-Correa E; Rodriguez RC; Axenhus M; Weiss SS; Batenburg K; Hoozemans JJM; Tjernberg LO; Scheper W
Alzheimers Res Ther; 2022 Dec; 14(1):196. PubMed ID: 36578089
[TBL] [Abstract][Full Text] [Related]
20. Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer's Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression.
Tolar M; Hey J; Power A; Abushakra S
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34198582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
